Valneva shares fall 2.5% and drop back below their MM50, near the bottom of the SBF 120

A 2.43% decline that brings the stock back below its MM50

Valneva shares fell 2.43% to €2.57 at the close, while the SBF 120 gained 0.05%. This decline places it in the lower part of the index, far from leading stocks such as Teleperformance (+2.93%). It erases part of the rebound of recent days, which had lifted the recovery to the €2.68 resistance the previous day.

The stock thus falls back below its MM50, at €2.63, i.e. 2.36% above the price, while remaining above its MM20 at €2.51. The MM200, at €2.85, remains significantly higher.

The RSI at 51 is neutral: the day's move looks more like a pause than a breakout, especially since the €2.68 resistance has just been tested and the support lies at €2.33.

Chikungunya data and regulatory milestones in the background

Over the week, the stock is nearly flat (+0.47%), following closely spaced clinical publications. Valneva published phase 2 results for its shigellosis vaccine on November 9, then on November 10 released new data on Ixchiq, with seroresponse maintained at 94% five years after a single dose.

At the publication of H1 2026 results, on August 13, the group confirmed its 2026 outlook despite the persistent negative impact of the geopolitical context on travel. It had also mentioned expected regulatory decisions on its Lyme disease candidate within the following twelve months.

Over three months, the stock is up 4.39%; over one year, it is down 34.39%. The dual listing (ordinary shares in Paris, ADSs on the Nasdaq) leaves Paris by far dominant in volumes. Next event for the stock: the Jefferies Global Healthcare conference, on November 16.